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ABSTRACT 
The mini-review focuses on the cancer therapy treatment efficacy as enhanced through combination and co-delivery methods. The 
focus is on nano-delivery methods and how in spite of the challenges in developing co-delivery, their potential is analyzed across 
different clinical fields.  
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INTRODUCTION 
Cancer therapy treatments are often questioned and 
verified with clinical efficiency trials. It has been identified 
that combination therapy often has a considerable 
improvement on the response rate in cancer patients1-8. It 
improves the drug resistance effects that reduce response 
rates argue, the combination of chemotherapy and related 
anticancer drugs are more effective and feasible. In fact, co-
delivery of anticancer drugs with nanotechnology is 
considered as one of the foremost desired forms of drug 
delivery9-17. This article presents a review of the co-
delivery of drugs and some of the positive response rates 
reported in such co-delivery. The scope of the paper is 
restricted to reviewing the actions of cancer treatment 
with combination and co-delivery. Only secondary 
research evidence is used in the review.  
COMBINATION AND CO-DELIVERY 
Combination chemotherapy drugs that make use of two 
and more anti-cancer drugs are more effective and feasible 
in clinical practice. Combination therapy is a therapeutic 
intervention so constructed that the therapy or medication 
administered to the cancer patient is more than one18-25. It 
could be the administration of different medicines or 
administration of different treatment plans involving more 
than one medicine. Researchers like Qi et al.26,27  and Han 
et al.2 in their research work have identified that 
combinatory forms with co-delivery are better for cancer 
treatment.
  
 
Figure 1: In-vitro drug release profile and stability, (Han et al., 2017) 
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Combination chemotherapy drugs would not be significant 
on their own when it comes to enhancing treatment 
efficacy. In the chemotherapeutic treatments on malignant 
cancer, it has been identified that drug resistance is a 
significant issue. MDR results in the state where the 
treatment dosages have to be significantly increased26,28-31. 
The toxicity of the drugs used to fight cancer cells attacks 
normal cells. Very high dosages of the drug as necessitated 
by the multidrug resistance (MDR) hence result in 
significant health issues, toxicity issues and sometimes 
even the death of the patient. In this context, combination 
drugs were considered as a solution, but then the co-
administration of different therapeutic drugs in themselves 
cannot bring much of a clinical advantage. The combined 
drugs had different pharmacokinetic properties. Only the 
use of nanomedicine and nanotechnology-based co-
delivery are helpful in this situation27,32-35. Co-delivery is 
therefore necessary for achieving said benefits. Co-delivery 
has the capacity of reversing the effects of MDR. 
  
 
Figure 2: MDR reversal, (Sun et al., 2016) 
 
Co-delivery systems help deliver these combination 
treatment plans. Nanodrug based co-delivery systems 
NDCDS have been assessed as a strategy of choice by 
researchers Qi et al.27 where two different drugs which are 
different in physicochemical and pharmacological 
properties were used as part of a combination delivery 
system. The use of such drugs resulted in synergistic 
inhibition of growth of tumors as compared to other drugs. 
This shows the possibility of nanoparticle co-delivery and 
combination drug therapy in the prospective future. Han et 
al. argue about the efficacy of combination drugs in tumor 
reduction. Their work is focused on usage of multiple 
anticancer agents delivered as a drug encapsulated 
dendritic nano micelles36-39. The parallel activity of 5-
fluorouracil (5-Fu) and doxorubicin (Dox) results in 
synergistic anticancer efficacy. In specific, Han et al. noted 
that the combined cytotoxicity of the treatment drugs on 
human breast cancer cells of the MDA-MB-231 type 
increased by 11.2 and 6.1. In other forms of cancer cells, 
like brain tumors, Kang et al.  place the argument that 
nano-delivery forms have better chances of crossing the 
blood-brain barrier. The increased cytotoxicity inhibits 
tumor cells from growing, and the progression of the 
growth is controlled. These forms of combination trials 
pave the way for multiple co-encapsulation of 
chemotherapy drugs which would be useful for treating 
cancer. In the case of gene delivery to cancer cells, 
researchers like Yang et al. (2016) even support the 
significance of nanoscaled EMs. Thus, Co-delivery systems 
as shown in the work of Han et al.2  and Qi et al.27  play a 
significant role in the delivery of combination drugs. 
Design of co-delivery systems is of many types such as 
nano micelles, nanoparticles, and liposomes. Drug loading 
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capacity is high in these co-delivery systems. They are able 
to reach and deliver chemotherapeutic agents to the tumor 
regions because of their permeability and retention 
aspects. While there are many advantages in using the 
combination and co-delivery systems, there are some 
challenges to using them. The nano-delivery systems have 
limited stability. The diameter distribution is very 
dispersed, and they can be used only with certain drugs. 
Adaption to many drugs with these nano-delivery systems 
is still investigated and until then the co-delivery systems 
cannot be used in a large scale in clinics. However, as the 
research work of Han et al.  highlights, there is potential for 
development. Co-delivery systems are studied across 
different medical fields like anti-cancer treatment and anti-
psychosis. Han et al.2 designed AmD with hydrophilic 
polyamidoamine dendrons and hydrophobic poly. Once 
they are self-assembled into nano-delivery micelles, they 
work to co-encapsulate the medications and deliver them 
to the designated regions. Preferential drug release aspects 
make them work on targeted tumor lesions instead of 
attacking normal cells. Cytotoxicity is enhanced in the 
tumor lesions more and the overall drug efficacy is 
enhanced because of targeted action that is promoted by 
the co-delivery technique. Therefore, in spite of the main 
challenges that are present in combination and co-delivery, 
researchers work on finding optimal solutions that can 
support multiple drugs.  
CONCLUSION 
The review conducted on combination therapy with co-
delivery shows that the combination methods in 
themselves are not that effective given that they are 
different in their pharmacokinetic properties. It is the use 
of co-delivery systems that enhance their efficacy. 
Research works have been conducted on the nano-delivery 
system and their effects on brain tumors and breast 
cancers are documented. Future research hence has to 
focus on extending the form of co-delivery systems. 
  
REFERENCES 
1. Kang C., Qin J., Osei W. & Hu K. Age-dependent Mitochondrial 
Targeting Of Protein Kinase C Epsilon In Cardioprotection. 
The FASEB Journal (2017). 
2. Han R., Sun Y., Kang C., Sun H. & Wei W. Amphiphilic dendritic 
nanomicelle-mediated co-delivery of 5-fluorouracil and 
doxorubicin for enhanced therapeutic efficacy. Journal of 
Drug Targeting 2017; 25:140-148. 
3. Duan Y., et al. Bioactivity evaluation-based ultra high-
performance liquid chromatography coupled with 
electrospray ionization tandem quadrupole-time-of-flight 
mass spectrometry and novel distinction of multi-
subchemome compatibility recognition strategy with 
Astragali Radix-Fructus Corni herb-pair as a case study. J 
Pharm Biomed Anal 2016; 129:514-534. 
4. Sun Y., et al. Co-delivery of dual-drugs with nanoparticle to 
overcome multidrug resistance. European Journal of 
BioMedical Research 2016; 2:12-18. 
5. Ai R., et al. Comprehensive epigenetic landscape of 
rheumatoid arthritis fibroblast-like synoviocytes. Nat 
Commun 2018; 9:1921. 
6. Fan S., et al. Computationally expanding infinium 
HumanMethylation450 BeadChip array data to reveal distinct 
DNA methylation patterns of rheumatoid arthritis. 
Bioinformatics 2016; 32:1773-1778. 
7. Liu F., Sun Y. & Kang C. Controlling Amphiphilic Functional 
Block Copolymers’ Self-Assembly: From Structure to Size. 
(2016). 
8. Song L., et al. Crocetin inhibits lipopolysaccharide-induced 
inflammatory response in human umbilical vein endothelial 
cells. Cellular Physiology and Biochemistry 2016; 40:443-452. 
9. Sun Y., Kang C., Liu F. & Song L. Delivery of antipsychotics 
with nanoparticles. Drug Development Research 77, 393-399 
(2016). 
10. Kang C., et al. Delivery of nanoparticles for treatment of brain 
tumor. Current Drug Metabolism 2016; 17:745-754. 
11. Xue X., et al. Discovery of novel inhibitors disrupting HIF-
1α/von Hippel–Lindau interaction through shape-based 
screening and cascade docking. PeerJ 2016; 4:e2757. 
12. Hersch S.J., et al. Divergent protein motifs direct elongation 
factor P-mediated translational regulation in Salmonella 
enterica and Escherichia coli. MBio 2013; 4:e00180-00113. 
13. Shuhong X., et al. Dynamic expression of AQP4 in early 
stageof ischemia/reperfusion rats and cerebral edema. 
Chinese Pharmacological Bulletin 2016; 32:1433-1441. 
14. Peng J., et al. Enhanced Liver Regeneration After Partial 
Hepatectomy in Sterol Regulatory Element-Binding Protein 
(SREBP)-1c-Null Mice is Associated with Increased 
Hepatocellular Cholesterol Availability. Cellular Physiology 
and Biochemistry 2018; 47:784-799. 
15. Yang, Z., et al. Functional exosome-mimic for delivery of 
siRNA to cancer: in vitro and in vivo evaluation. Journal of 
Controlled Release 2016; 243:160-171. 
16. Kang C., Hernandez V.A. & Hu K. Functional interaction of the 
two-pore domain potassium channel TASK-1 and caveolin-3. 
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 
2017; 1864:1537-1544. 
17. Waller A.P., et al. GLUT12 functions as a basal and insulin-
independent glucose transporter in the heart. Biochimica et 
Biophysica Acta (BBA)-Molecular Basis of Disease 2013; 
1832:121-127. 
18. Li Q., et al. Identification by shape-based virtual screening 
and evaluation of new tyrosinase inhibitors. PeerJ 2018; 
6:e4206. 
19. Chen, Y., et al. Identification of 4-aminoquinoline core for the 
design of new cholinesterase inhibitors. PeerJ 2016; 4:e2140. 
20. Kang C. & Hu K. Impact of hypoxia in the expression and 
regulation of the TASK-1 potassium channel in cardiac 
myocytes. The FASEB Journal 2016; 30:lb598-lb598. 
21. Kang C. Ion channels, protein kinase C and caveolae in 
cardioprotection, (The Ohio State University, 2015). 
22. Yung B.C., et al. Lipid nanoparticles composed of quaternary 
amine–tertiary amine cationic lipid combination (QTsome) 
for therapeutic delivery of AntimiR-21 for lung cancer. 
Molecular pharmaceutics 2016; 13:653-662. 
23. Cheng X., et al. Lipid Nanoparticles Loaded with an Antisense 
Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung 
Cancer. Pharmaceutical research 2017; 34:310-320. 
24. Fan S. & Chi W. Methods for genome-wide DNA methylation 
analysis in human cancer. Brief Funct Genomics 2016; 
15:432-442. 
25. Kang C. & Hu K. Modulation of the two-pore domain 
potassium channel TASK-1 by caveolin-3. The FASEB Journal 
2015; 29:845.814. 
26. Qiao H., et al. Orally delivered polycurcumin responsive to 
bacterial reduction for targeted therapy of inflammatory 
bowel disease. Drug Delivery 2017; 24:233-242. 
Zhang et al                                                                                                                              Journal of Drug Delivery & Therapeutics. 2018; 8(6):261-264  
ISSN: 2250-1177                                                                                   [264]                                                                                   CODEN (USA): JDDTAO 
27. Qiao H., et al. Redox-triggered mitoxantrone prodrug micelles 
for overcoming multidrug-resistant breast cancer. Journal of 
drug targeting 2018; 26:75-85. 
28. Kang C., Sun Y., Wang,M. & Cheng X. Nanosized camptothecin 
conjugates for single and combined drug delivery. European 
Journal of BioMedical Research 2016; 2:8-14. 
29. Liu F., Sun Y., Kang C. & Zhu H. Pegylated Drug Delivery 
Systems: From Design to Biomedical Applications. Nano LIFE 
2016; 6:1642002. 
30. Sun Y., Kang C., Yao Z., Liu F. & Zhou Y. Peptide-Based Ligand 
for Active Delivery of Liposomal Doxorubicin. Nano Life 2016; 
6:1642004. 
31. Fan S., Huang K., Ai R., Wang M. & Wang W. Predicting CpG 
methylation levels by integrating Infinium 
HumanMethylation450 BeadChip array data. Genomics 2016; 
107:132-137. 
32. Kang C., Qin J., Osei W. & Hu K. Regulation of protein kinase C-
epsilon and its age-dependence. Biochemical and Biophysical 
Research Communications 2017; 482:1201-1206. 
33. Sun Y., et al. RGD Peptide‐Based Target Drug Delivery of 
Doxorubicin Nanomedicine. Drug development research 2017; 
78:283-291. 
34. Kang C. & Hu K. Role of caveolin-3 in adenosine-induced 
increase in mitochondrial PKCε. The FASEB Journal 2013; 
27:1191.1197-1191.1197. 
35. Cheng X. & Lee R.J. The role of helper lipids in lipid 
nanoparticles (LNPs) designed for oligonucleotide delivery. 
Adv Drug Deliv Rev 2016; 99:129-137. 
36. Sun Y. & Kang C. Self-Assembly of Peptides into Hydrogel. 
Journal of Organic & Inorganic Chemistry 2016; 2:5. 
37. Yao Z., Sun Y. & Kang C. Structure and self-assembly of 
multicolored Naphthalene Diimides Semiconductor. Nano 
LIFE 2016; 6:1642007. 
38. Cheng X., et al. T7 Peptide-Conjugated Lipid Nanoparticles for 
Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical 
Carcinomas. Molecular pharmaceutics 2018; 15:4722-4732. 
39. Zhong X., Sun Y., Kang C. & Wan G. The theory of 
dielectrophoresis and its applications on medical and 
materials research. European Journal of BioMedical Research 
2017; 2:7-11. 
 
 
